Latest information on COVID-19
Support teaching, research, and patient care.
Dr. Philip Hanno specializes in the treatment of urologic chronic pain syndromes including bladder pain syndrome/interstitial cystitis and chronic pelvic pain syndrome in men (nonbacterial prostatitis). He sees patients with voiding dysfunction, urinary tract infection, and general urologic problems as well. From 1981 to 1990 he was an Associate Professor of Urology at the Hospital of the University of Pennsylvania and Chief of Urology at the Philadelphia Veterans Administration Medical Center. For the next decade he was Chairman of Urology at Temple University School of Medicine. After a year as a medical officer in the Food and Drug Administration in Washington, he returned to the University of Pennsylvania in 1999 as Professor of Urology. He came to Stanford in October 2016. He has studied bladder pain syndrome both from a basic science and clinical perspective for much of his career and has published extensively on the syndrome. He is co-chair of the Medical Advisory Board of the Interstitial Cystitis Association and on the executive board of the International Society for the Study of Bladder Pain Syndrome (ESSIC). He is the past Chair of the Bladder Pain Syndrome Guideline Committee of the American Urological Association.Dr. Hanno focuses on the non-operative management of common urologic conditions with his special interest being helping patients with urologic chronic pain syndromes.
Design clinical trials to evaluate new treatments for bladder pain syndrome
Low-dose Naltrexone for Bladder Pain Syndrome
Interstitial cystitis/Bladder Pain Syndrome (IC/PBS) is a constellation of symptoms of pelvic
discomfort that includes both bladder-related pain as well as urinary frequency, urgency, and
nocturia in the absence of an identifiable etiology that affects likely more than 5.4 million
patients in the United States. There is a significant overlap in patients with IC/PBS and
those with fibromyalgia and chronic pelvic pain syndrome. Low-dose naltrexone (LDN) has been
shown to be effective for the treatment of chronic pain conditions.
The primary aim of this study is to evaluate if LDN improves pain scores and lower urinary
tract symptoms in patients with IC/PBS. A secondary aim is to show that it has a low adverse
View full details